|
Showing 1 - 6 of
6 matches in All Departments
This expert volume in the Diagnostic Pathology series is an
excellent point-of-care resource for practitioners at all levels of
experience and training. Covering the full range of nonneoplastic
and neoplastic conditions of the female genital tract, it
incorporates the most recent scientific and technical knowledge in
the field to provide a comprehensive overview of all key issues
relevant to today's practice. Richly illustrated and easy to use,
the third edition of Diagnostic Pathology: Gynecological is a
visually stunning, one-stop resource for every practicing
pathologist, resident, student, or fellow as an ideal day-to-day
reference or as a reliable training resource. Covers all areas of
gynecologic pathology, organized into six easy-to-reference
anatomic Covers all areas of gynecologic pathology, organized into
seven easy-to-reference anatomic sections: vulva, vagina, uterine
cervix, uterine corpus, fallopian tube and broad ligament, ovary,
and peritoneum Includes all frequently encountered conditions plus
extensive coverage of uncommon entities, such as inflammatory
diseases of the vulva, discussed by experts in dermatopathology
Provides updated differential diagnoses and diagnostic pearls as
well as extensive revisions based on the 2020 WHO Classification of
Tumors: Female Genital Tumors, including staging issues and
measurement standards Reflects important molecular updates in
endometrial carcinoma classifications as well as updated
classifications for squamous and glandular tumors for the lower
genital tract, both in situ and invasive Updates ancillary
techniques, newly encountered pitfalls, and advances in the
molecular landscape of epithelial and mesenchymal tumors Features
more than 2,500 superb images in print and online, including many
new gross and microscopic images as well as diagnostically relevant
immunohistochemical and molecular findings Includes an eBook
version that enables you to access all text, figures, and
references, with the ability to search, customize your content,
make notes and highlights, and have content read aloud
Since the publication of the Third Series Fascicle of the Uterine
Corpus nearly thirty years ago, molecular discoveries have deepened
our understanding of epithelial, mesenchymal, and mixed mullerian
tumors of the uterus, fueling a new and still evolving
classification of the different categories of uterine neoplasms.
Enormous insights have been made to refine the classification of
the different subtypes of endometrial carcinoma linked to important
prognostic and therapeutic implications. At the same time,
molecular findings have allowed for the discovery of familial
syndromes associated with uterine corpus neoplasms, and
identification of patients at increased risk for developing
specific tumors, with the subsequent implementation of genetic
counseling and appropriate treatment guidelines. Molecular
underpinnings have also assisted in the development of new and
potentially more predictive morphologic criteria for endometrial
preneoplasia, namely the endometrial intraepithelial neoplasia (or
EIN) system. In this Uterine Corpus Fascicle, there is an increased
emphasis on the cytopathologic (intraoperative, exfoliative, or
fine needle aspiration) and molecular features that are important
in diagnosis and prognosis. What does not change from the three
previous series, however, is the goal of providing the reader with
thorough, concise, and up-to-date information on the nomenclature
and classification; epidemiologic, clinical, and pathogenetic
features; and, most importantly, guidance in the diagnosis of the
tumors and tumorlike lesions of all major organ systems and body
sites. Order the Tumors of the Uterine Corpus and Trophoblastic
Diseases now to take advantage of these new discoveries and
techniques for diagnosing and treating these types of tumors.
There are more than 63,000 new cases of uterine and endometrial
cancer each year in the United States, up from approximately 41,000
when the first edition of Uterine Cancer was published in 2009. A
book focusing on these cancers was timely, with emergent
sophistication in diagnosis increasingly impacting clinical
decision-making. However, five years later, the need for an updated
book on this topic is even stronger as oncologists recognize
opportunities to impact the outcome on women that are increasingly
diagnosed with these malignancies. Uterine Cancer: Screening,
Diagnosis, and Treatment, Second Edition, part of the Current
Clinical Oncology series, enhances the awareness on this somewhat
neglected area of therapeutics, helping to integrate targeted
therapies into the management of women with uterine cancer. Written
by experts in the field in a highly practical and comprehensive
manner, it is a must-have for all gynecological residents and
fellows, as well as gynecological oncologists, medical oncologists,
radiation oncologists, and family practice doctors who wish to
provide their patients with the best possible care.
There are more than 63,000 new cases of uterine and endometrial
cancer each year in the United States, up from approximately 41,000
when the first edition of Uterine Cancer was published in 2009. A
book focusing on these cancers was timely, with emergent
sophistication in diagnosis increasingly impacting clinical
decision-making. However, five years later, the need for an updated
book on this topic is even stronger as oncologists recognize
opportunities to impact the outcome on women that are increasingly
diagnosed with these malignancies. Uterine Cancer: Screening,
Diagnosis, and Treatment, Second Edition, part of the Current
Clinical Oncology series, enhances the awareness on this somewhat
neglected area of therapeutics, helping to integrate targeted
therapies into the management of women with uterine cancer. Written
by experts in the field in a highly practical and comprehensive
manner, it is a must-have for all gynecological residents and
fellows, as well as gynecological oncologists, medical oncologists,
radiation oncologists, and family practice doctors who wish to
provide their patients with the best possible care.
For the Editors, the task of writing a Preface is most satisfying.
It represents the completion of the book and a moment of reflection
on whether the whole is more than the sum of all the parts. And
also, one must reflect on how this book is likely to be utilized in
this era of rapid communications. The Editors first met in May 2003
at a stimulating Italian symposium on endometrial cancer
(organizers Drs. Luigi Frigerio, Roberto Grassi and Andrea Lissoni,
with participation of the deans of Italian Gynecologic Oncology,
Ugo Bianchi and Constantino Mangioni) that took place at Bergamo
and Caravaggio. The impressive gains in biology and clinical trials
were further discussed by the two editors and others that are
co-authors in this venture on this side of the Atlantic at a 2004
Educational Session at the American Society of Clinical Oncology
(ASCO). The pace of progress in various aspects of management of
uterine cancer was no- worthy, not only was tumor biology fueling
novel hypotheses such as questioning the mesenchymal origin of
carcinosarcomas, but knowledge of molecular pathways was beginning
to be applied as prognostic and as predictive factors portending
benefit from systemic therapies. Surgical staging and sensitive
imaging provided the underpinning for refining our treatment
algorithms. Finally, a role for che- therapy had finally become
established, principally through phase III studies c- paring
chemotherapy to radiation in mostly locally advanced stages III and
IV that had undergone resection.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|